Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Harnessing Self-Assembling Peptides on γδ T Cells to Enhance Anti-Tumor Immunity.

Polymer science & technology (Washington, D.C.)·2026
Same author

Anionic or Mixed-Charge Copolypeptides with Potent Antibiofilm Activities.

Biomacromolecules·2026
Same author

Mitofusin-Decorated Extracellular Vesicles Enable Targeted Nucleic Acid Delivery to Mitochondria.

Nano letters·2026
Same author

Inflammation-responsive hierarchical delivery of anti-inflammatory siRNA and peptide alleviates cytokine storm in pneumonia.

Biomaterials science·2026
Same author

A Two-Step Approach Combining Steatosis Biomarkers and Multiparametric Quantitative US Enhances Noninvasive Diagnosis of Hepatic Steatosis.

Ultrasound in medicine & biology·2026
Same author

Enhanced corneal retention of hyaluronic acid <i>via</i> a metabolic glycoengineering-based <i>in vivo</i> bioorthogonal reaction.

Biomaterials science·2026
Same journal

Fiber and continuum scale contributions to the intrinsic and apparent fracture of soft collagenous tissue <i>via</i> cutting.

Biomaterials science·2026
Same journal

Surface morphology-regulated tissue adhesion in solid and mesoporous silica-reinforced gelatin nanocomposite hydrogels.

Biomaterials science·2026
Same journal

Nanostructured hyaluronic acid-chia mucilage film as bioactive wound dressings for accelerated skin regeneration.

Biomaterials science·2026
Same journal

Tunable bio-inspired hybrid hydrogels reprogram stem cell-derived extracellular vesicles for superior wound regeneration.

Biomaterials science·2026
Same journal

Bioorthogonally reinforced injectable granular hydrogels synergizing ECM mimicry with microporosity for skin tissue engineering.

Biomaterials science·2026
Same journal

Modeling a hypoxia-integrated glioblastoma microenvironment to mimic tumor heterogeneity and chemoresistance.

Biomaterials science·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2026

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

Light-programmable, high-drug-loading nanomedicine based on dimeric camptothecin.

Lei Wu1,2, Yehan Wang1, Kaimin Cai3

  • 1Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Collaborative Innovation Center of Suzhou Nano Science & Technology, Soochow University, Suzhou 215123, China. lcyin@suda.edu.cn.

Biomaterials Science
|June 17, 2026
PubMed
Summary
This summary is machine-generated.

This study developed light-programmable nanoparticles (hQCC NPs) that co-deliver a photosensitizer and a chemotherapy drug for enhanced cancer treatment. The nanoparticles leverage photodynamic therapy to improve drug release and efficacy while minimizing side effects.

More Related Videos

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Related Experiment Videos

Last Updated: Jun 18, 2026

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Area of Science:

  • Nanomedicine
  • Biotechnology
  • Materials Science

Background:

  • Efficient nano-encapsulation of hydrophobic drugs and controlled release are key challenges in nanomedicine.
  • Hydrophobic drugs like camptothecin (CPT) often aggregate during nanoformulation, limiting drug loading and efficacy.
  • Hypoxia, a common feature of solid tumors, can reduce the effectiveness of some cancer therapies.

Purpose of the Study:

  • To design light-programmable, high-drug-loading nanoparticles (hQCC NPs) for synergistic cancer treatment.
  • To co-encapsulate a photosensitizer (Ce6) and a hypoxia-activatable CPT prodrug (hQ-CPT2) within PEG-PLA nanoparticles.
  • To investigate the potential of converting tumor hypoxia from a challenge into a therapeutic advantage.

Main Methods:

  • Developed quinone-modified hQ-CPT2 to disrupt CPT aggregation and enhance nanoformulation.
  • Co-encapsulated Ce6 and hQ-CPT2 into PEG-PLA nanoparticles (hQCC NPs).
  • Evaluated the synergistic antitumor effects of Ce6-mediated photodynamic therapy (PDT) and CPT chemotherapy in 4T1 and MCF-7 tumor models.

Main Results:

  • Achieved ultra-high drug-loading capacity (46.8%) and near 100% loading efficiency for hQCC NPs.
  • Demonstrated that light-activated Ce6-PDT generates ROS and aggravates intratumoral hypoxia, facilitating hQ-CPT2 release.
  • Observed pronounced antitumor efficacy and inhibition of tumor metastasis in vivo with minimal off-target toxicity.
  • Showcased synergistic interaction between PDT and chemotherapy, with CPT inhibiting hypoxia-inducible factor-1α upregulation.

Conclusions:

  • hQCC NPs offer a promising nanoplatform for spatiotemporally controlled combination cancer therapy.
  • The strategy effectively converts tumor hypoxia into a therapeutic advantage, enhancing treatment outcomes.
  • This light-programmable approach provides a potential strategy for programmable combination cancer therapy with reduced toxicity.